- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Syfovre Complications Discussed in Late-Breakers Session | AAO 2023
Suber S. Huang, M.D., MBA, a panelist for a session about late-breaking research, said the presentation about Syfovre complications among patients treated at the Wolfe Eye Clinic in Iowa is one of the most important of this year's annual meeting. Five patients experienced complications from the new drug for geographic atrophy.
In an interview with Managed Healthcare Executive, Suber S. Huang, M.D., MBA, of the Retina Center of Ohio in Cleveland, said the late-breaking presentation by William J. Johnson, M.D., of Wolfe Eye Clinic in Iowa about complications from Syfovre (pegacetacoplan) was “an extremely important” paper. Huang said that although Syfovre has been “successfully and safely used in thousands of patients,” there have been a number of cases of hemorrhagic occlusive vasculitis among treated patients that have led to moderate to severe visual loss.
In his presentation, Johnson discussed five cases of Syfovre complications among the 96 eyes treated with the new drug by Wolfe Eye Clinic retina specialists. In July 2023 the clinic paused use of the drug, according to Johnson.
PHOTON Study of 8-mg Eylea Suggests Some Patients Could Be Treated Just Two Times a Year | AAO 2023
November 5th 2023Approximately one-third of the patients assigned to 16-week intervals of 8-mg formulation of Eylea changed to a 24-week interval during the second year of. the study, according results presented at the annual meeting of the American Academy of Ophthalmology. The PHOTON study enrolled people with diabetic macular edema.
Read More
Teleophthalmology: One Way To Help Span the Healthcare Disparity Divide | AAO 2023
November 5th 2023Albert S. Khouri, M.D., a professor of ophthalmology at the Rutgers New Jersey Medical School, discusses teleophthalmology’s role in outreach efforts and improving ophthalmic care in the emergency room.
Read More
